Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of JYB1904 plus background therapy in perennial allergic rhinitis
CTR20260733Phase 2Active
- Sponsor
- Jiangsu Jiye Biopharmaceutical
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ozureprubart in perennial rhinitis, sponsored by Jiangsu Jiye Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
ozureprubart
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on CTR20260733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260733.